FRAMINGHAM, MA -- (MARKET WIRE) -- 10/20/2005 -- Symbollon Pharmaceuticals, Inc. (OTC BB: SYMBA) today announced its intention to start a clinical trial that will focus on the treatment of patients with proliferative benign breast disease. The open-label, single-center study will evaluate the clinical effects of IoGen™, an oral dosage form of Symbollon’s proprietary molecular iodine technology, in about 20 women.
